National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting, 5195 [05-1840]

Download as PDF Federal Register / Vol. 70, No. 20 / Tuesday, February 1, 2005 / Notices is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Mental Health Special Emphasis Panel, Imaging and Mood Disorders. Date: February 23, 2005. Time: 12 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone conference call). Contact Person: Peter J. Sheridan, PhD, Scientific Review Administrator, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC 9606, Bethesda, MD 20892–9606, 301–443–1513, psherida@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS) Dated: January 26, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–1839 Filed 1–31–05; 8:45 am] will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Type 1 Diabetes— Rapid Access to Intervention Development Special Emphasis Panel, National Institute of Diabetes and Digestive and Kidney Diseases. Date: February 9, 2005. Time: 10 a.m.–2 p.m. Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications. Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone conference call). Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes Translation Research, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, MD 20892– 5460, 301–402–7886. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Disease and Nutrition Research; 98.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: January 26, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 05–1840 Filed 1–31–05; 8:45 am] BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes. The outcome of the evaluation National Institutes of Health 15:06 Jan 31, 2005 Jkt 205001 as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes. The outcome of the evaluation will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Type 1 Diabetes— Rapid Access to Intervention Development Special Emphasis Panel, National Institute of Diabetes and Digestive and Kidney Diseases. Date: February 18, 2005. Time: 2 a.m.–4 p.m. Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications. Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone conference call). Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes Translation Research, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, MD 20892– 5460, (301) 402–7886. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research, 98.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: January 26, 2005. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–1842 Filed 1–31–05; 8:45 am] BILLING CODE 4140–01–M National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting VerDate jul<14>2003 5195 National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Library of Medicine; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections E:\FR\FM\01FEN1.SGM 01FEN1

Agencies

[Federal Register Volume 70, Number 20 (Tuesday, February 1, 2005)]
[Notices]
[Page 5195]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-1840]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney 
Disorders; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. appendix 2) notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for type 1 diabetes. The outcome of the evaluation will be a decision 
whether NIDDK should support the request and make available contract 
resources for development of the potential therapeutic to improve the 
treatment or prevent the development of type 1 diabetes and its 
complications. The research proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Type 1 Diabetes--Rapid Access to Intervention 
Development Special Emphasis Panel, National Institute of Diabetes 
and Digestive and Kidney Diseases.
    Date: February 9, 2005.
    Time: 10 a.m.-2 p.m.
    Agenda: To evaluate requests for preclinical development 
resources for potential new therapeutics for type 1 diabetes and its 
complications.
    Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone 
conference call).
    Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes 
Translation Research, Division of Diabetes, Endocrinology and 
Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, 
MD 20892-5460, 301-402-7886.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Disease and Nutrition Research; 98.849, Kidney Diseases, Urology and 
Hematology Research, National Institutes of Health, HHS)


    Dated: January 26, 2005.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

[FR Doc. 05-1840 Filed 1-31-05; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.